Table of Contents
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. CAR-T Cell Therapy Market – Premium Insights
3.1. CAR-T Cell Therapy– Industry snapshot
3.2. CAR-T Cell Therapy- Ecosystem analysis
3.3. CAR-T Cell Therapy Market dynamics
3.3.1. CAR-T Cell Therapy– Market Forces
3.3.1.1. CAR-T Cell Therapy Market driver analysis
3.3.1.2. CAR-T Cell Therapy Market restraint/challenges analysis
3.3.1.3. CAR-T Cell Therapy Market opportunity analysis
3.4. Industry analysis - Porter's five force analysis
3.5. CAR-T Cell Therapy Market PEST analysis, 2019
3.6. CAR-T Cell Therapy Industry trends
3.7. Competitive Ranking Analysis
3.8. Timeline of CAR-T Cell Therapy Development
3.9. CAR-T Cell Manufacturing Process
3.10. Side-effects of CAR-T Cell
3.11. Antigens targeting solid tumors
3.12. Clinical trials Landscape for CAR-T
3.13. Commercial Landscape (Mergers & Acquisitions, Partnerships & Collaborations)
3.14. New Innovations in CAR-T therapies
4. CAR-T Cell Therapy Market Size and Forecast 2017 - 2026 by Target Antigen
4.1. Key findings
4.2. CD19/CD22
4.2.1. Global CD19/CD22 market estimates & forecast, 2017 – 2026
4.2.2. Global CD19/CD22 market estimates & forecast, by region, 2017 - 2026
4.3. BCMA (B-Cell Maturation Antigen)
4.3.1. Global BCMA market estimates & forecast, 2017 - 2026
4.3.2. Global BCMA market estimates & forecast, by region, 2017 - 2026
4.4. Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)
4.4.1. Global Other Target Antigen market estimates & forecast, 2017 - 2026
4.4.2. Global Other Target Antigen market estimates & forecast, by region, 2017 - 2026
5. CAR-T Cell Therapy Market Size and Forecast by Indication
5.1. Key findings
5.2. Diffuse Large B-Cell Lymphoma (DLBCL)
5.2.1. Global DLBCL market estimates & forecast, 2017 - 2026
5.2.2. Global DLBCL market estimates & forecast, by region, 2017 - 2026
5.3. Acute Lymphoblastic Leukemia (ALL)
5.3.1. Global ALL market estimates & forecast, 2017 - 2026
5.3.2. Global ALL market estimates & forecast, by region, 2017 - 2026
5.4. Chronic Lymphocytic Leukemia (CLL)
5.4.1. Global CLL market estimates & forecast, 2017 - 2026
5.4.2. Global CLL market estimates & forecast, by region, 2017 - 2026
5.5. Multiple Myeloma (MM)
5.5.1. Global MM market estimates & forecast, 2017 - 2026
5.5.2. Global MM market estimates & forecast, by region, 2017 - 2026
5.6. Follicular Lymphoma (FL)
5.6.1. Global FL market estimates & forecast, 2017 - 2026
5.6.2. Global FL market estimates & forecast, by region, 2017 - 2026
5.7. Others
5.7.1. Global Other indications market estimates & forecast, 2017 - 2026
5.7.2. Global Other indications market estimates & forecast, by region, 2017 - 2026
6. CAR-T Cell Therapy Market Size and Forecast by Regions
6.1. Key findings
6.2. U.S.
6.2.1. U.S. CAR-T Cell Therapy Market by Target Antigen, 2017-2026
6.2.2. U.S. CAR-T Cell Therapy Market by Indication, 2017 - 2026
6.3. Europe
6.3.1. Europe CAR-T Cell Therapy Market by Target Antigen, 2017 - 2026
6.3.2. Europe CAR-T Cell Therapy Market by Indication, 2017 - 2026
6.4. Japan
6.4.1. Japan CAR-T Cell Therapy Market by Target Antigen, 2017 - 2026
6.4.2. Japan CAR-T Cell Therapy Market by Indication, 2017 - 2026
6.5. Rest of the World
6.5.1. RoW CAR-T Cell Therapy Market by Target Antigen, 2017 - 2026
6.5.2. RoW CAR-T Cell Therapy Market by Indication, 2017 - 2026
7. Company Profiles
7.1. Amgen Inc. (US)
7.1.1. Overview
7.1.2. Financials
7.1.3. Product Benchmarking
7.1.4. Recent Developments
7.2. Bellicum Pharmaceuticals, Inc. (US)
7.2.1. Overview
7.2.2. Financials
7.2.3. Product Benchmarking
7.2.4. Recent Developments
7.3. Bluebird Bio (US)
7.3.1. Overview
7.3.2. Financials
7.3.3. Product Benchmarking
7.3.4. Recent Developments
7.4. Caribou Biosciences, Inc. (US)
7.4.1. Overview
7.4.2. Financials
7.4.3. Product Benchmarking
7.4.4. Recent Developments
7.5. Celgene Corporation (US) (acquired by Bristol-Myers Squibb)
7.5.1. Overview
7.5.2. Financials
7.5.3. Product Benchmarking
7.5.4. Recent Developments
7.6. Cellectis (France)
7.6.1. Overview
7.6.2. Financials
7.6.3. Product Benchmarking
7.6.4. Recent Developments
7.7. Celyad (Belgium)
7.7.1. Overview
7.7.2. Financials
7.7.3. Product Benchmarking
7.7.4. Recent Developments
7.8. Gilead Sciences, Inc. (US)
7.8.1. Overview
7.8.2. Financials
7.8.3. Product Benchmarking
7.8.4. Recent Developments
7.9. Intellia Therapeutics (US)
7.9.1. Overview
7.9.2. Financials
7.9.3. Product Benchmarking
7.9.4. Recent Developments
7.10. Johnson & Johnson (US)
7.10.1. Overview
7.10.2. Financials
7.10.3. Product Benchmarking
7.10.4. Recent Developments
7.11. Mereck KGaA (Germany)
7.11.1. Overview
7.11.2. Financials
7.11.3. Product Benchmarking
7.11.4. Recent Developments
7.12. Nanjing Legend Biotechnology Co., Ltd. (China)
7.12.1. Overview
7.12.2. Financials
7.12.3. Product Benchmarking
7.12.4. Recent Developments
7.13. Noile-Immune Biotech (Japan)
7.13.1. Overview
7.13.2. Financials
7.13.3. Product Benchmarking
7.13.4. Recent Developments
7.14. Novartis International AG (Swiss)
7.14.1. Overview
7.14.2. Financials
7.14.3. Product Benchmarking
7.14.4. Recent Developments
7.15. Pfizer Inc. (US)
7.15.1. Overview
7.15.2. Financials
7.15.3. Product Benchmarking
7.15.4. Recent Developments
7.16. Sangamo Therapeutics, Inc. (US)
7.16.1. Overview
7.16.2. Financials
7.16.3. Product Benchmarking
7.16.4. Recent Developments
7.17. Servier Laboratories (France)
7.17.1. Overview
7.17.2. Financials
7.17.3. Product Benchmarking
7.17.4. Recent Developments
